Cel-Sci Corp (CVM) 0.65 $CVM
Global Herpes Simplex Infections Therapeutics Pipeline Report H2 2014 - Analysis of 31 Companies & 46 Drug Profiles
M2 - Mon Nov 10, 10:43AM CST
Research and Markets (http://www.researchandmarkets.com/research/lk8z5n/herpes_simplex) has announced the addition of the "Herpes Simplex Infections - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Herpes Simplex Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Herpes Simplex Infections and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Sanofi - GenVec, Inc. - Astellas Pharma Inc. - CEL-SCI Corporation - Mymetics Corporation - NovaBay Pharmaceuticals, Inc. - Peregrine Pharmaceuticals, Inc. - Oryzon Genomics S.A. - Colby Pharmaceutical Company - ViroStatics, srl - Osel Inc. - AlphaVax, Inc. - Romark Laboratories, L.C. - Chimerix, Inc. - NanoBio Corporation - Immunovaccine, Inc. - Immune Design Corp. - Seek - Adamis Pharmaceuticals Corporation - Vaxart, Inc. - Genocea Biosciences, Inc. - Pharis Biotec GmbH - Profectus BioSciences, Inc. - 3-V Biosciences, Inc. - PaxVax - Spider Biotech - Kala Pharmaceuticals, Inc. - Vaccibody AS - Sanofi Pasteur SA - Humabs BioMed SA Drug Profiles - amenamevir - GEN-003 - herpes simplex virus vaccine - HSV-529 - brincidofovir - CEL-1000 - Vaccine for Herpes Simplex Infections - herpes simplex vaccine [HSV-2] - C-31G - Cyanovirin-N for Infectious Disease - GEN-002 - NVC-727 - NVC-638 - NVC-704 - JVRS-100 Herpes Simplex Virus-2 Vaccine - Drug for Herpes Simplex - PGN-632 - G-103 - GV-2207 - acyclovir - SB-105 - Monoclonal Antibodies for HIV and Herpes Simplex Infections - Synthetic Peptide for Oncology and Infectious Disease - herpes simplex virus vaccine - MB-66 - Small Molecule to Inhibit Fatty Acid Synthase for Viral Infections - BA-368 - HSV-2 Vaccine - Small Molecule Inhibiting Kinases for Viral Infections - mab hu2c For more information visit http://www.researchandmarkets.com/research/lk...es_simplex
IMDZ: 35.22 (-0.75), CMRX: 32.24 (-0.68), CVM: 0.65 (+0.04), ADMP: 4.09 (+0.15), GNCA: 8.90 (-0.04)
Head And Neck Cancer Squamous Cell Carcinoma Therapeutics Pipeline Report 2014 - 32 Companies & 65 DRug Profiles
M2 - Mon Nov 10, 10:26AM CST
Research and Markets (http://www.researchandmarkets.com/research/wml9ch/head_and_neck) has announced the addition of the "Head And Neck Cancer Squamous Cell Carcinoma - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Head And Neck Cancer Squamous Cell Carcinoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Head And Neck Cancer Squamous Cell Carcinoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Bristol-Myers Squibb Company - Boehringer Ingelheim GmbH - F. Hoffmann-La Roche Ltd. - Shionogi & Co., Ltd. - Amgen Inc. - Eli Lilly and Company - GlaxoSmithKline plc - Celltrion, Inc. - Novartis AG - Eisai Co., Ltd. - ImmunoGen, Inc. - Santaris Pharma A/S - CEL-SCI Corporation - OXiGENE, Inc. - Takara Bio Inc. - Panacea Biotec Limited - PCI Biotech AS - Nanobiotix - Acceleron Pharma, Inc. - Virttu Biologics Limited - Ascenta Therapeutics, Inc. - Onconova Therapeutics, Inc. - Genexine, Inc. - Viventia Biotechnologies Inc. - Oncovir, Inc. - Gliknik, Inc. - Karyopharm Therapeutics, Inc. - Agonox - Tolero Pharmaceuticals, Inc. - AlphaMab Co., Ltd For more information visit http://www.researchandmarkets.com/research/wm...d_and_neck
CVM: 0.65 (+0.04), IMGN: 9.53 (+0.07), AMGN: 157.68 (-3.17), LLY: 67.33 (-0.35), ONTX: 4.69 (-0.13), BMY: 57.95 (+0.15), GSK: 45.74 (+0.08), OXGN: 1.98 (+0.22), XLRN: 33.50 (-1.81), KPTI: 39.77 (-0.66), NVS: 93.95 (-0.43)
CEL-SCI Enrolls 22 Patients During October in Its Phase III Immunotherapy Head and Neck Cancer Trial
Business Wire - Mon Nov 03, 7:30AM CST
CEL-SCI Corporation (NYSE MKT:CVM) today announced that during the month of October the Company enrolled 22 patients with advanced primary, not yet treated, head and neck cancer into its global pivotal Phase III head and neck cancer trial for its investigational immunotherapy Multikine* (Leukocyte Interleukin, Injection). This brings the total number patients enrolled in the world's largest Phase III trial for head and neck cancer to almost 300. A total of 880 patients are expected to be enrolled, through 100 clinical centers in over 20 countries.
CVM: 0.65 (+0.04)
CEL-SCI raises USD6m from public offering of common stock & warrants
M2 - Mon Oct 27, 6:06AM CDT
Oncology company CEL-SCI (NYSE MKT:CVM) reported on Friday that it has completed a public offering of 7,894,737 shares of common stock and 1,973,684 warrants to purchase shares of its common stock.
CVM: 0.65 (+0.04)
CEL-SCI Corporation Announces Closing of Public Offering for Gross Proceeds of $6 Million
Business Wire - Fri Oct 24, 9:09AM CDT
CEL-SCI Corporation (NYSE MKT: CVM), a late-stage oncology company, today announced that it has closed an underwritten public offering of 7,894,737 shares of common stock and 1,973,684 warrants to purchase shares of common stock. For every four shares of common stock sold, we issued to investors in this offering one warrant to purchase a share of common stock. The common stock and warrants were sold at a combined price of $0.76 and resulted in aggregate gross proceeds of $6 million, prior to deducting underwriting commissions and offering expenses and excluding the exercise of any warrants. The common stock and warrants will separate immediately. The warrants are immediately exercisable, expire October 11, 2018, have an exercise price of $1.25 and trade on the NYSE MKT under the symbol "CVM WS".
CVM: 0.65 (+0.04)
Investors look to Lighten Up on Shares of CEL-SCI, Shares Down 20.6% (CVM)
Comtex SmarTrend(R) - Tue Oct 21, 10:13AM CDT
CEL-SCI (AMEX:CVM) is one of today's worst performing penny stocks, down 20.6% to $0.68 on 7.0x average daily volume. Thus far today, CEL-SCI has traded 2.0 million shares, vs. average volume of 285,000 shares per day. The stock has underperformed the Dow (-20.6% to the Dow's 0.6%) and underperformed the S&P 500 (-20.6% to the S&P's 1.2%) during today's trading.
CVM: 0.65 (+0.04)
CEL-SCI Corporation to Raise $1 Million in Registered Direct Offering
Business Wire - Tue Oct 21, 8:42AM CDT
CEL-SCI Corporation (NYSE MKT: CVM), a late-stage oncology company, has agreed to sell common stock and warrants in a registered direct offering to European investors at a combined price of $0.76 for aggregate gross proceeds of a little over $1 million. For every four shares sold, we will issue to investors in this offering one warrant to purchase a share of common stock. The warrants are immediately exercisable, expire October 11, 2018, have an exercise price of $1.25 and trade on the NYSE MKT under the symbol "CVM WS". The offering is expected to close on or about October 24, 2014, subject to the satisfaction of customary closing conditions.
CVM: 0.65 (+0.04)
CEL-SCI Corporation Prices $6 Million Public Offering of Common Stock and Warrants
Business Wire - Tue Oct 21, 8:15AM CDT
CEL-SCI Corporation (NYSE MKT: CVM), a late-stage oncology company, today announced that it has priced a "best efforts" underwritten public offering of common stock and warrants at a combined price of $0.76 for aggregate gross proceeds of $6 million, prior to deducting underwriting commissions and offering expenses and excluding the exercise of any warrants. For every four shares sold, we will issue to investors in this offering one warrant to purchase a share of common stock. The warrants are immediately exercisable, expire October 11, 2018, have an exercise price of $1.25 and trade on the NYSE MKT under the symbol "CVM WS". The offering is expected to close on or about October 24, 2014, subject to the satisfaction of customary closing conditions.
CVM: 0.65 (+0.04)
CEL-SCI Corporation Announces Proposed Public Offering of Common Stock and Warrants
Business Wire - Mon Oct 20, 3:30PM CDT
CEL-SCI Corporation (NYSE MKT: CVM), a late-stage oncology company, today announced that it intends to offer and sell common stock and warrants in an underwritten public offering. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed.
CVM: 0.65 (+0.04)
Warts Therapeutics Pipeline Review 2014
M2 - Mon Oct 13, 6:40AM CDT
Research and Markets (http://www.researchandmarkets.com/research/wc94mt/warts_pipeline) has announced the addition of the "Warts - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Warts, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Warts and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Helix BioPharma Corp. - CEL-SCI Corporation - NanoViricides, Inc. - 3M Drug Delivery Systems - G&E Herbal Biotechnology Co., Ltd. - Anaconda Pharma - Foamix Ltd. - BioMAS Ltd. - ViroStatics, srl - Cutanea Life Sciences - Burke Pharmaceuticals, LLC - Agilvax, Inc. - Nielsen Biosciences, Inc. Drug Profiles - interferon alpha-2b (recombinant) - AS-101 - SRT-100 - AP-611074 - Candida Albicans Antigen - (digoxin furosemide) - Leukocyte Interleukin - A-101 - BURKE-201 - AX-03 - HerpeCide-I - imiquimod - 854-A - PP-210 - Small Molecule to Inhibit CDK9 for HPV Associated Cancers and Warts For more information visit http://www.researchandmarkets.com/research/wc...s_pipeline
CVM: 0.65 (+0.04), NNVC: 3.39 (-0.08)
CEL-SCI Enrolls 16 Patients in September in Its Phase III Immunotherapy Head and Neck Cancer Trial
Business Wire - Fri Oct 03, 8:15AM CDT
CEL-SCI Corporation (NYSE MKT: CVM) today announced that during the month of September the Company enrolled 16 patients with advanced primary, not yet treated, head and neck cancer into its global pivotal Phase III head and neck cancer trial for its investigational immunotherapy Multikine* (Leukocyte Interleukin, Injection).
CVM: 0.65 (+0.04)
Coverage Initiation Report Focuses on CEL-SCI Corporation
Marketwire - Wed Oct 01, 10:33AM CDT
CEL-SCI Corporation (NYSE MKT: CVM) is the subject of an in-depth initiation coverage report by Acceleron Equity Research.
CVM: 0.65 (+0.04)
4 Stocks Under $10 Making Big Moves Higher
at The Street - Wed Oct 01, 6:00AM CDT
hen a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
CVM: 0.65 (+0.04), PLUG: 3.72 (-0.34), NYNY: 7.62 (+0.42), MERU: 3.78 (-0.09)
CEL-SCI & U.S. Navy Administer Multikine to First Volunteer Patient in Phase I Clinical Trial for Treatment of Anal Warts in HIV/HPV Co-Infected Patients
Business Wire - Mon Sep 29, 7:00AM CDT
CEL-SCI Corporation (NYSE MKT: CVM) today announced the first volunteer patient has been enrolled and administered Multikine* (Leukocyte Interleukin, Injection) in a Institutional Review Board approved Phase I Clinical Trial evaluating peri-anal wart immunotherapy in HIV/HPV co-infected men and women at the Naval Medical Center San Diego (NMCSD). The purpose of this dose escalation study is to evaluate the safety and impact of Multikine as a treatment of Human Papilloma Virus associated peri-anal warts and assess the effect on anal intraepithelial dysplasia (AIN) in HIV/HPV co-infected men and women.
CVM: 0.65 (+0.04)
Hot Stock: CEL-SCI, Shares Drop 5.5% (CVM)
Comtex SmarTrend(R) - Tue Sep 23, 11:36AM CDT
CEL-SCI (AMEX:CVM) is one of today's worst performing penny stocks, down 5.5% to $0.81 on 1.1x average daily volume. CEL-SCI has traded 263,000 shares thus far today, vs. average volume of 234,000 shares per day. The stock has underperformed the Dow (-4.9% to the Dow's -0.3%) and underperformed the S&P 500 (-4.9% to the S&P's -0.3%) during today's trading.
CVM: 0.65 (+0.04)
Valuation Analysis for CEL-SCI
ACCESSWIRE - Thu Sep 11, 5:18AM CDT
Los Angeles, CA / September 11, 2014 / On Wednesday, CEL-SCI Corporation (NYSEMKT: CVM) made public the fact that the respected University of Minnesota's Masonic Cancer Center has become part of the company's Phase III head and neck cancer clinical trial. This is the 7th clinical site in the U.S. to join CEL-SCI's late stage study for its investigational cancer immunotherapy treatment Multikine* (Leukocyte Interleukin, Injection).
CVM: 0.65 (+0.04)
University of Minnesota Masonic Cancer Center Joins CEL-SCI's Phase III Head & Neck Cancer Trial
Business Wire - Wed Sep 10, 7:45AM CDT
CEL-SCI Corporation (NYSE MKT: CVM) today announced that the University of Minnesota's Masonic Cancer Center has becomes the 7th clinical site in the U.S. to join its Phase III head and neck cancer clinical trial of its investigational cancer immunotherapy treatment Multikine* (Leukocyte Interleukin, Injection).
CVM: 0.65 (+0.04)
Smallpox Therapeutics Pipeline Review Report 2014 - 15 Companies & 16 Drug Profiles
M2 - Wed Sep 10, 4:33AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hdcds3/smallpox) has announced the addition of the "Smallpox - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Smallpox, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Smallpox and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Inovio Pharmaceuticals, Inc. - Bavarian Nordic A/S - Symphogen A/S - Nanotherapeutics, Inc. - CEL-SCI Corporation - SIGA Technologies, Inc. - TapImmune Inc. - CJ CheilJedang Corp. - MacroGenics, Inc. - AlphaVax, Inc. - EpiVax, Inc. - Chimerix, Inc. - Conkwest, Inc. - Inhibikase Therapeutics, Inc. - Polyrizon Ltd. Drug Profiles - smallpox vaccine [Modified Vaccinia Ankara - Bavarian Nordic Virus] - CJ-50300 - brincidofovir - Sym-002 - cidofovir - CEL-1000 - tecovirimat - DNA Vaccine for Smallpox - Smallpox Vaccine - CST-102 - DNA Vaccine for Smallpox - TPIV-300 - imatinib mesylate - Monoclonal Antibody for Infectious Disease - PL-801 - Smallpox Vaccine For more information visit http://www.researchandmarkets.com/research/hdcds3/smallpox
MGNX: 23.27 (-0.86), CMRX: 32.24 (-0.68), CVM: 0.65 (+0.04), SIGA: 1.60 (-0.07)
CEL-SCI Enrolls 20 Patients in August in Its Phase III Immunotherapy Head and Neck Cancer Trial
Business Wire - Wed Sep 03, 7:01AM CDT
CEL-SCI Corporation (NYSE MKT:CVM) today announced that it enrolled 20 patients with advanced primary, not yet treated, head and neck cancer into its global pivotal Phase III head and neck cancer trial for its investigational immunotherapy Multikine* (Leukocyte Interleukin, Injection) during August 2014. This brings the total study enrollment to 252 patients.
CVM: 0.65 (+0.04)
Global Herpes Simplex Infections Therapeutics Pipeline Report H2 2014 - Analysis of 31 Companies & 46 Drug Profiles
M2 - Mon Nov 10, 10:43AM CST
Research and Markets (http://www.researchandmarkets.com/research/lk8z5n/herpes_simplex) has announced the addition of the "Herpes Simplex Infections - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Herpes Simplex Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Herpes Simplex Infections and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Sanofi - GenVec, Inc. - Astellas Pharma Inc. - CEL-SCI Corporation - Mymetics Corporation - NovaBay Pharmaceuticals, Inc. - Peregrine Pharmaceuticals, Inc. - Oryzon Genomics S.A. - Colby Pharmaceutical Company - ViroStatics, srl - Osel Inc. - AlphaVax, Inc. - Romark Laboratories, L.C. - Chimerix, Inc. - NanoBio Corporation - Immunovaccine, Inc. - Immune Design Corp. - Seek - Adamis Pharmaceuticals Corporation - Vaxart, Inc. - Genocea Biosciences, Inc. - Pharis Biotec GmbH - Profectus BioSciences, Inc. - 3-V Biosciences, Inc. - PaxVax - Spider Biotech - Kala Pharmaceuticals, Inc. - Vaccibody AS - Sanofi Pasteur SA - Humabs BioMed SA Drug Profiles - amenamevir - GEN-003 - herpes simplex virus vaccine - HSV-529 - brincidofovir - CEL-1000 - Vaccine for Herpes Simplex Infections - herpes simplex vaccine [HSV-2] - C-31G - Cyanovirin-N for Infectious Disease - GEN-002 - NVC-727 - NVC-638 - NVC-704 - JVRS-100 Herpes Simplex Virus-2 Vaccine - Drug for Herpes Simplex - PGN-632 - G-103 - GV-2207 - acyclovir - SB-105 - Monoclonal Antibodies for HIV and Herpes Simplex Infections - Synthetic Peptide for Oncology and Infectious Disease - herpes simplex virus vaccine - MB-66 - Small Molecule to Inhibit Fatty Acid Synthase for Viral Infections - BA-368 - HSV-2 Vaccine - Small Molecule Inhibiting Kinases for Viral Infections - mab hu2c For more information visit http://www.researchandmarkets.com/research/lk...es_simplex
IMDZ: 35.22 (-0.75), CMRX: 32.24 (-0.68), CVM: 0.65 (+0.04), ADMP: 4.09 (+0.15), GNCA: 8.90 (-0.04)
Head And Neck Cancer Squamous Cell Carcinoma Therapeutics Pipeline Report 2014 - 32 Companies & 65 DRug Profiles
M2 - Mon Nov 10, 10:26AM CST
Research and Markets (http://www.researchandmarkets.com/research/wml9ch/head_and_neck) has announced the addition of the "Head And Neck Cancer Squamous Cell Carcinoma - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Head And Neck Cancer Squamous Cell Carcinoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Head And Neck Cancer Squamous Cell Carcinoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Bristol-Myers Squibb Company - Boehringer Ingelheim GmbH - F. Hoffmann-La Roche Ltd. - Shionogi & Co., Ltd. - Amgen Inc. - Eli Lilly and Company - GlaxoSmithKline plc - Celltrion, Inc. - Novartis AG - Eisai Co., Ltd. - ImmunoGen, Inc. - Santaris Pharma A/S - CEL-SCI Corporation - OXiGENE, Inc. - Takara Bio Inc. - Panacea Biotec Limited - PCI Biotech AS - Nanobiotix - Acceleron Pharma, Inc. - Virttu Biologics Limited - Ascenta Therapeutics, Inc. - Onconova Therapeutics, Inc. - Genexine, Inc. - Viventia Biotechnologies Inc. - Oncovir, Inc. - Gliknik, Inc. - Karyopharm Therapeutics, Inc. - Agonox - Tolero Pharmaceuticals, Inc. - AlphaMab Co., Ltd For more information visit http://www.researchandmarkets.com/research/wm...d_and_neck
CVM: 0.65 (+0.04), IMGN: 9.53 (+0.07), AMGN: 157.68 (-3.17), LLY: 67.33 (-0.35), ONTX: 4.69 (-0.13), BMY: 57.95 (+0.15), GSK: 45.74 (+0.08), OXGN: 1.98 (+0.22), XLRN: 33.50 (-1.81), KPTI: 39.77 (-0.66), NVS: 93.95 (-0.43)
CEL-SCI Enrolls 22 Patients During October in Its Phase III Immunotherapy Head and Neck Cancer Trial
Business Wire - Mon Nov 03, 7:30AM CST
CEL-SCI Corporation (NYSE MKT:CVM) today announced that during the month of October the Company enrolled 22 patients with advanced primary, not yet treated, head and neck cancer into its global pivotal Phase III head and neck cancer trial for its investigational immunotherapy Multikine* (Leukocyte Interleukin, Injection). This brings the total number patients enrolled in the world's largest Phase III trial for head and neck cancer to almost 300. A total of 880 patients are expected to be enrolled, through 100 clinical centers in over 20 countries.
CVM: 0.65 (+0.04)
CEL-SCI raises USD6m from public offering of common stock & warrants
M2 - Mon Oct 27, 6:06AM CDT
Oncology company CEL-SCI (NYSE MKT:CVM) reported on Friday that it has completed a public offering of 7,894,737 shares of common stock and 1,973,684 warrants to purchase shares of its common stock.
CVM: 0.65 (+0.04)
CEL-SCI Corporation Announces Closing of Public Offering for Gross Proceeds of $6 Million
Business Wire - Fri Oct 24, 9:09AM CDT
CEL-SCI Corporation (NYSE MKT: CVM), a late-stage oncology company, today announced that it has closed an underwritten public offering of 7,894,737 shares of common stock and 1,973,684 warrants to purchase shares of common stock. For every four shares of common stock sold, we issued to investors in this offering one warrant to purchase a share of common stock. The common stock and warrants were sold at a combined price of $0.76 and resulted in aggregate gross proceeds of $6 million, prior to deducting underwriting commissions and offering expenses and excluding the exercise of any warrants. The common stock and warrants will separate immediately. The warrants are immediately exercisable, expire October 11, 2018, have an exercise price of $1.25 and trade on the NYSE MKT under the symbol "CVM WS".
CVM: 0.65 (+0.04)
Investors look to Lighten Up on Shares of CEL-SCI, Shares Down 20.6% (CVM)
Comtex SmarTrend(R) - Tue Oct 21, 10:13AM CDT
CEL-SCI (AMEX:CVM) is one of today's worst performing penny stocks, down 20.6% to $0.68 on 7.0x average daily volume. Thus far today, CEL-SCI has traded 2.0 million shares, vs. average volume of 285,000 shares per day. The stock has underperformed the Dow (-20.6% to the Dow's 0.6%) and underperformed the S&P 500 (-20.6% to the S&P's 1.2%) during today's trading.
CVM: 0.65 (+0.04)
CEL-SCI Corporation to Raise $1 Million in Registered Direct Offering
Business Wire - Tue Oct 21, 8:42AM CDT
CEL-SCI Corporation (NYSE MKT: CVM), a late-stage oncology company, has agreed to sell common stock and warrants in a registered direct offering to European investors at a combined price of $0.76 for aggregate gross proceeds of a little over $1 million. For every four shares sold, we will issue to investors in this offering one warrant to purchase a share of common stock. The warrants are immediately exercisable, expire October 11, 2018, have an exercise price of $1.25 and trade on the NYSE MKT under the symbol "CVM WS". The offering is expected to close on or about October 24, 2014, subject to the satisfaction of customary closing conditions.
CVM: 0.65 (+0.04)
CEL-SCI Corporation Prices $6 Million Public Offering of Common Stock and Warrants
Business Wire - Tue Oct 21, 8:15AM CDT
CEL-SCI Corporation (NYSE MKT: CVM), a late-stage oncology company, today announced that it has priced a "best efforts" underwritten public offering of common stock and warrants at a combined price of $0.76 for aggregate gross proceeds of $6 million, prior to deducting underwriting commissions and offering expenses and excluding the exercise of any warrants. For every four shares sold, we will issue to investors in this offering one warrant to purchase a share of common stock. The warrants are immediately exercisable, expire October 11, 2018, have an exercise price of $1.25 and trade on the NYSE MKT under the symbol "CVM WS". The offering is expected to close on or about October 24, 2014, subject to the satisfaction of customary closing conditions.
CVM: 0.65 (+0.04)
CEL-SCI Corporation Announces Proposed Public Offering of Common Stock and Warrants
Business Wire - Mon Oct 20, 3:30PM CDT
CEL-SCI Corporation (NYSE MKT: CVM), a late-stage oncology company, today announced that it intends to offer and sell common stock and warrants in an underwritten public offering. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed.
CVM: 0.65 (+0.04)
Warts Therapeutics Pipeline Review 2014
M2 - Mon Oct 13, 6:40AM CDT
Research and Markets (http://www.researchandmarkets.com/research/wc94mt/warts_pipeline) has announced the addition of the "Warts - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Warts, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Warts and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Helix BioPharma Corp. - CEL-SCI Corporation - NanoViricides, Inc. - 3M Drug Delivery Systems - G&E Herbal Biotechnology Co., Ltd. - Anaconda Pharma - Foamix Ltd. - BioMAS Ltd. - ViroStatics, srl - Cutanea Life Sciences - Burke Pharmaceuticals, LLC - Agilvax, Inc. - Nielsen Biosciences, Inc. Drug Profiles - interferon alpha-2b (recombinant) - AS-101 - SRT-100 - AP-611074 - Candida Albicans Antigen - (digoxin furosemide) - Leukocyte Interleukin - A-101 - BURKE-201 - AX-03 - HerpeCide-I - imiquimod - 854-A - PP-210 - Small Molecule to Inhibit CDK9 for HPV Associated Cancers and Warts For more information visit http://www.researchandmarkets.com/research/wc...s_pipeline
CVM: 0.65 (+0.04), NNVC: 3.39 (-0.08)
CEL-SCI Enrolls 16 Patients in September in Its Phase III Immunotherapy Head and Neck Cancer Trial
Business Wire - Fri Oct 03, 8:15AM CDT
CEL-SCI Corporation (NYSE MKT: CVM) today announced that during the month of September the Company enrolled 16 patients with advanced primary, not yet treated, head and neck cancer into its global pivotal Phase III head and neck cancer trial for its investigational immunotherapy Multikine* (Leukocyte Interleukin, Injection).
CVM: 0.65 (+0.04)
Coverage Initiation Report Focuses on CEL-SCI Corporation
Marketwire - Wed Oct 01, 10:33AM CDT
CEL-SCI Corporation (NYSE MKT: CVM) is the subject of an in-depth initiation coverage report by Acceleron Equity Research.
CVM: 0.65 (+0.04)
4 Stocks Under $10 Making Big Moves Higher
at The Street - Wed Oct 01, 6:00AM CDT
hen a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
CVM: 0.65 (+0.04), PLUG: 3.72 (-0.34), NYNY: 7.62 (+0.42), MERU: 3.78 (-0.09)
CEL-SCI & U.S. Navy Administer Multikine to First Volunteer Patient in Phase I Clinical Trial for Treatment of Anal Warts in HIV/HPV Co-Infected Patients
Business Wire - Mon Sep 29, 7:00AM CDT
CEL-SCI Corporation (NYSE MKT: CVM) today announced the first volunteer patient has been enrolled and administered Multikine* (Leukocyte Interleukin, Injection) in a Institutional Review Board approved Phase I Clinical Trial evaluating peri-anal wart immunotherapy in HIV/HPV co-infected men and women at the Naval Medical Center San Diego (NMCSD). The purpose of this dose escalation study is to evaluate the safety and impact of Multikine as a treatment of Human Papilloma Virus associated peri-anal warts and assess the effect on anal intraepithelial dysplasia (AIN) in HIV/HPV co-infected men and women.
CVM: 0.65 (+0.04)
Hot Stock: CEL-SCI, Shares Drop 5.5% (CVM)
Comtex SmarTrend(R) - Tue Sep 23, 11:36AM CDT
CEL-SCI (AMEX:CVM) is one of today's worst performing penny stocks, down 5.5% to $0.81 on 1.1x average daily volume. CEL-SCI has traded 263,000 shares thus far today, vs. average volume of 234,000 shares per day. The stock has underperformed the Dow (-4.9% to the Dow's -0.3%) and underperformed the S&P 500 (-4.9% to the S&P's -0.3%) during today's trading.
CVM: 0.65 (+0.04)
Valuation Analysis for CEL-SCI
ACCESSWIRE - Thu Sep 11, 5:18AM CDT
Los Angeles, CA / September 11, 2014 / On Wednesday, CEL-SCI Corporation (NYSEMKT: CVM) made public the fact that the respected University of Minnesota's Masonic Cancer Center has become part of the company's Phase III head and neck cancer clinical trial. This is the 7th clinical site in the U.S. to join CEL-SCI's late stage study for its investigational cancer immunotherapy treatment Multikine* (Leukocyte Interleukin, Injection).
CVM: 0.65 (+0.04)
University of Minnesota Masonic Cancer Center Joins CEL-SCI's Phase III Head & Neck Cancer Trial
Business Wire - Wed Sep 10, 7:45AM CDT
CEL-SCI Corporation (NYSE MKT: CVM) today announced that the University of Minnesota's Masonic Cancer Center has becomes the 7th clinical site in the U.S. to join its Phase III head and neck cancer clinical trial of its investigational cancer immunotherapy treatment Multikine* (Leukocyte Interleukin, Injection).
CVM: 0.65 (+0.04)
Smallpox Therapeutics Pipeline Review Report 2014 - 15 Companies & 16 Drug Profiles
M2 - Wed Sep 10, 4:33AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hdcds3/smallpox) has announced the addition of the "Smallpox - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Smallpox, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Smallpox and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Inovio Pharmaceuticals, Inc. - Bavarian Nordic A/S - Symphogen A/S - Nanotherapeutics, Inc. - CEL-SCI Corporation - SIGA Technologies, Inc. - TapImmune Inc. - CJ CheilJedang Corp. - MacroGenics, Inc. - AlphaVax, Inc. - EpiVax, Inc. - Chimerix, Inc. - Conkwest, Inc. - Inhibikase Therapeutics, Inc. - Polyrizon Ltd. Drug Profiles - smallpox vaccine [Modified Vaccinia Ankara - Bavarian Nordic Virus] - CJ-50300 - brincidofovir - Sym-002 - cidofovir - CEL-1000 - tecovirimat - DNA Vaccine for Smallpox - Smallpox Vaccine - CST-102 - DNA Vaccine for Smallpox - TPIV-300 - imatinib mesylate - Monoclonal Antibody for Infectious Disease - PL-801 - Smallpox Vaccine For more information visit http://www.researchandmarkets.com/research/hdcds3/smallpox
MGNX: 23.27 (-0.86), CMRX: 32.24 (-0.68), CVM: 0.65 (+0.04), SIGA: 1.60 (-0.07)
CEL-SCI Enrolls 20 Patients in August in Its Phase III Immunotherapy Head and Neck Cancer Trial
Business Wire - Wed Sep 03, 7:01AM CDT
CEL-SCI Corporation (NYSE MKT:CVM) today announced that it enrolled 20 patients with advanced primary, not yet treated, head and neck cancer into its global pivotal Phase III head and neck cancer trial for its investigational immunotherapy Multikine* (Leukocyte Interleukin, Injection) during August 2014. This brings the total study enrollment to 252 patients.
CVM: 0.65 (+0.04)
